Dovonex, a topical vitamin D derivative, reduces excessive skin cell production and therefore helps improve the symptoms of psoriasis. It is sold under the brand name Daivonex in certain European, South American, and Asian markets. Although the current availability of various formulations differs by market, Dovonex is manufactured as an ointment or a cream for psoriasis plaques on the body and as a lotion (solution) for scalp psoriasis.
While Dovonex (calcipotriol; Leo Pharma) was historically the most popular topical vitamin derivative in the psoriasis market, owing to its proven efficacy and safety, its patient share has seen a steady decline since 2007 owing to expiries of its molecule and ointment formulation patents. The strategic 2001 launch of Dovobet, a combination of calcipotriol and betamethasone, helped Leo Pharma retain a significant proportion of patient share lost to generics of its Dovonex ointment.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Dovonex : Psoriasis
LIST OF FIGURES
9 Figure 1: Dovonex for psoriasis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Dovonex in psoriasis
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Dovonex in psoriasis
LIST OF TABLES
4 Table 1: Dovonex drug profile
7 Table 2: Dovonex pivotal trial data in psoriasis
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.